Explore KEYTRUDA® patient profiles
- Patrick † A patient with squamous metastatic NSCLC
- Diane † A patient metastatic non-squamous NSCLC
- Mary † A patient with metastatic squamous NSCLC
Explore efficacy and safety profile results for KEYTRUDA® in the second-line setting for non-squamous metastatic NSCLC.
Discover results from the KEYNOTE-024 trialExplore efficacy and safety profile results for KEYTRUDA® in the second-line setting for non-squamous metastatic NSCLC.
Discover results from the KEYNOTE-189 trialExplore efficacy and safety profile results for KEYTRUDA® in the second-line setting for non-squamous metastatic NSCLC.
Discover results from the KEYNOTE-407 trialExplore efficacy and safety profile results for KEYTRUDA® in the second-line setting for non-squamous metastatic NSCLC.
Discover results from the KEYNOTE-010 trialALK=anaplastic lymphoma kinase; CT=computed tomography; ECOG PS=Eastern Cooperative Oncology Group performance status; EGFR=epidermal growth factor receptor; NSCLC=non-small cell lung carcinoma; PD-L1=programmed cell death ligand 1; TPS=tumour proportion score
† Fictitious patient. May not be representative of the entire patient population.
‡ X-Ray and CT Scan from Rastogi M, et al. BMJ Case Rep. 2016
References:
1. Merck Canada Inc. KEYTRUDA® Product Monograph. April 19, 2023.
2. ASCO and OH (CCO) Joint Guideline Update. Available at: https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/62681
3. Hanna, N et al. (2020). Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(14), 1608–1632. https://doi.org/10.1200/JCO.19.03022
4. Rastogi M, et al. (2016). An unusual response with long term survival using erlotinib in NSCLC lung with brain metastases. BMJ Case Rep. bcr2015213239. https://doi.org/10.1136/bcr-2015-213239
5. Medline. Available at: https://medlineplus.gov/ency/imagepages/1183.htm
6. Dromain C, Beigelman C, Pozzessere C, Duran R, Digklia A. Imaging of tumour response to immunotherapy. Eur Radiol Exp. 2020 Jan 3;4(1):2.
CA-LAM-00050